2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-16482
    Teglicar 250694-07-6 ≥98.0%
    Teglicar is a selective and reversible orally active liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1) inhibitor with an IC50 value of 0.68 μM and a Ki value of 0.36 μM. Teglicar has a potential antihyperglycemic propert. Teglicar can be used for the research of diabetes and neurodegenerative disease including Huntington's disease (HD).
    Teglicar
  • HY-B1716
    L-5-Hydroxytryptophan 4350-09-8 99.83%
    L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist. L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia.
    L-5-Hydroxytryptophan
  • HY-P1024
    GLP-2(1-33)(human) 223460-79-5 98.73%
    GLP-2(1-33) (human) is an enteroendocrine hormone which can bind to the GLP-2 receptor and stimulate the growth of intestinal epithelium.
    GLP-2(1-33)(human)
  • HY-113224
    Desmosterol 313-04-2 ≥98.0%
    Desmosterol is a cholesterol-like molecule. In the Bloch pathway of cholesterol biosynthesis, Desmosterol is a direct precursor of cholesterol. As an endogenous metabolite, Desmosterol is used to study cholesterol metabolism . Desmosterol is an LXR activator and SREBP inhibitor, which can suppress macrophage inflammasome activation and prevent vascular inflammation and atherosclerosis. A reduction in Desmosterol promotes the production of mitochondrial reactive oxygen species (ROS) in macrophages and pyrin domain-dependent inflammasome activation of NLRP3. Desmosterol holds potential for research in inflammation, metabolism, and cardiovascular diseases .
    Desmosterol
  • HY-114360
    Taurohyodeoxycholic acid 2958-04-5 ≥98.0%
    Taurohyodeoxycholic acid is the tauroconjugated form of Hyodeoxycholic acid (HDCA, a dihydroxylated natural bile acid). Taurohyodeoxycholic acid induces a biliary phospholipid secretion and suggests a hepatoprotective potential. Taurohyodeoxycholic acid also can promote gallstone dissolution.
    Taurohyodeoxycholic acid
  • HY-126358
    Acetylcarnitine 14992-62-2 ≥98.0%
    Acetylcarnitine is an endogenous metabolite.
    Acetylcarnitine
  • HY-150508
    MK-0159 2641484-61-7 99.72%
    MK-0159 is an orally active, potent and selective CD38 inhibitor, with IC50 values of 22, 3, and 70 nM for human, mouse and rat CD38, respectively. MK-0159 also shows good microsomal stability for human and rodent liver microsomes. MK-0159 increases NAD+ (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart.
    MK-0159
  • HY-N0830S2
    Palmitic acid-d31 39756-30-4 ≥99.0%
    Palmitic acid-d31 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants. PA can induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in in mouse granulosa cells.
    Palmitic acid-d31
  • HY-W004283
    Pentadecanoic acid 1002-84-2 ≥98.0%
    Pentadecylic acid is a saturated fatty acid with a 15-carbon backbone.
    Pentadecanoic acid
  • HY-W008150
    2-Hydroxy-3-methylbutanoic acid 4026-18-0 ≥98.0%
    2-Hydroxy-3-methylbutanoic acid is an α-hydroxy analogue of valine and a valine precursor that reduces urea excretion. 2-Hydroxy-3-methylbutanoic acid can promote the growth of chickens and rats, and is converted into valine in the body, participating in protein synthesis and maintaining nitrogen balance, thereby supporting animal growth and development. 2-Hydroxy-3-methylbutanoic acid has a more significant effect on the valine-deficient dietary model. 2-Hydroxy-3-methylbutanoic acid is mainly used in animal nutrition research to evaluate its potential application as a nitrogen source substitute in feed.
    2-Hydroxy-3-methylbutanoic acid
  • HY-W013049
    Docosanoic acid 112-85-6 ≥98.0%
    Docosanoic acid (Behenic acid) is a long-chain saturated fatty acid. Docosanoic acid inhibits the double-stranded DNA (dsDNA) binding activity of p53 DNA binding domain, with a Kd of 12 nM. Docosanoic acid has low bioavailability and can increase cholesterol in humans.
    Docosanoic acid
  • HY-W011727A
    Pyridoxal 5'-​phosphate monohydrate 41468-25-1 ≥98.0%
    Pyridoxal 5'-phosphate monohydrate, the active form of vitamin B6, is an essential cofactor for multiple enzymes, including aromatic l-amino acid decarboxylase that catalyzes the final stage in the production of the neurotransmitters dopamine and serotonin. Pyridoxal 5'-phosphate monohydrate is the most important coenzyme variant in the process of vitamin B6 intracellular phosphorylation and is interconvertible with other variants, including pyridoxine 5′‐phosphate (PNP) and pyridoxamine 5′‐phosphate (PMP).
    Pyridoxal 5'-​phosphate monohydrate
  • HY-W030796A
    Lactisole 150436-68-3 99.86%
    Lactisole is a canonical antagonist of sweet taste receptor, selectively targeting to T1R3 subunit, a glucose-sensing receptor. Lactisole inhibits insulin secretion induced by glucose in mouse islets.
    Lactisole
  • HY-B0504S
    Creatinine-d3 143827-20-7 ≥99.0%
    Creatinine-d3 is a deuterium labeled Creatinine. Creatinine is a break-down product of creatine phosphate in muscle.
    Creatinine-d3
  • HY-P99116
    Faricimab 1607793-29-2
    Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO).
    Faricimab
  • HY-15258
    Lesinurad 878672-00-5 99.96%
    Lesinurad is a URAT1 and OAT inhibitor, is determined to be a substrate for the kidney transporters OAT1 and OAT3 with Km values of 0.85 and 2 µM, respectively.
    Lesinurad
  • HY-19618
    BRD3308 1550053-02-5 98.34%
    BRD3308 is a highly selective HDAC3 inhibitor with an IC50 of 54 nM. BRD3308 is 23-fold selectivity for HDAC3 over HDAC1 (IC50 of 1.26 μM) or HDAC2 (IC50 of 1.34 μM). BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. BRD3308 activates HIV-1 transcription and disrupts HIV-1 latency.
    BRD3308
  • HY-19657
    Oxypurinol 2465-59-0 ≥98.0%
    Oxipurinol (Oxipurinol), the major active metabolite of Allopurinol, is an inhibitor of xanthine oxidase. Oxipurinol can be used to regulate blood urate levels and treat gout.
    Oxypurinol
  • HY-59291
    Levacetylleucine 1188-21-2 ≥98.0%
    Levacetylleucine (N-acetyl-L-leucine), an orally bioavailable and brain-penetrant compound, is an acetylated derivative of amino acid Leucine. Levacetylleucine is the active form of N-acetyl-leucine (NAL). Levacetylleucine attenuates neuronal death and neuroinflammation in the cortical tissue of mice. Levacetylleucine also potentially improves ameliorates lysosomal and metabolic dysfunction. Levacetylleucine improves compensation of postural symptoms after unilateral chemical labyrinthectomy (UL) in rats. Levacetylleucine is promising for research of neurological manifestations of Niemann-Pick disease type C, traumatic brain injury and neurodegeneration prevention.
    Levacetylleucine
  • HY-B0760
    Fenofibric acid 42017-89-0 99.94%
    Fenofibric acid, an active metabolite of fenofibrate, is a PPAR activitor, with EC50s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC50 of 48 nM.
    Fenofibric acid
Cat. No. Product Name / Synonyms Application Reactivity